Schütz M - Search Results

1

FTY720 (fingolimod) in renal transplantation.

Budde K, Schütz M, Glander P, Peters H, Waiser J, Liefeldt L, Neumayer HH, Böhler T. Budde K, et al. Among authors: schutz m. Clin Transplant. 2006;20 Suppl 17:17-24. doi: 10.1111/j.1399-0012.2006.00596.x. Clin Transplant. 2006. PMID: 17100697 Review.

2

FTY720 mediates apoptosis-independent lymphopenia in human renal allograft recipients: different effects on CD62L+ and CCR5+ T lymphocytes.

Böhler T, Waiser J, Schütz M, Dragun D, Neumayer HH, Budde K. Böhler T, et al. Among authors: schutz m. Transplantation. 2004 May 15;77(9):1424-32. doi: 10.1097/01.tp.0000120539.94629.6a. Transplantation. 2004. PMID: 15167602 Clinical Trial.

3

Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients.

Böhler T, Schütz M, Budde K, Neumayer HH, Waiser J. Böhler T, et al. Among authors: schutz m. Int Immunopharmacol. 2007 Jan;7(1):88-95. doi: 10.1016/j.intimp.2006.08.018. Epub 2006 Sep 26. Int Immunopharmacol. 2007. PMID: 17161821 Clinical Trial.

4

FTY 720A mediates reduction of lymphocyte counts in human renal allograft recipients by an apoptosis-independent mechanism.

Böhler T, Waiser J, Schütz M, Friedrich M, Schötschel R, Reinhold S, Schmouder R, Budde K, Neumayer HH. Böhler T, et al. Among authors: schutz m. Transpl Int. 2000;13 Suppl 1:S311-3. doi: 10.1007/s001470050350. Transpl Int. 2000. PMID: 11112021 Clinical Trial.

5

Pharmacodynamics of FTY720, the first member of a new class of immune-modulating therapeutics in transplantation medicine.

Böhler T, Waiser J, Schütz M, Schumann B, Neumayer HH, Budde K. Böhler T, et al. Among authors: schutz m. Int J Clin Pharmacol Ther. 2003 Oct;41(10):482-7. doi: 10.5414/cpp41482. Int J Clin Pharmacol Ther. 2003. PMID: 14703955 Clinical Trial.

6

Limitations of C2 monitoring in renal transplant recipients.

Einecke G, Schütz M, Mai I, Fritsche L, Giessing M, Glander P, Neumayer HH, Budde K. Einecke G, et al. Among authors: schutz m. Nephrol Dial Transplant. 2005 Jul;20(7):1463-70. doi: 10.1093/ndt/gfh819. Epub 2005 Apr 19. Nephrol Dial Transplant. 2005. PMID: 15840681

7

Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series.

Lachmann N, Schütz M, Budde K, Schönemann C, Waiser J. Lachmann N, et al. Among authors: schutz m. Clin Transpl. 2009:351-8. Clin Transpl. 2009. PMID: 20527073

8

Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.

Waiser J, Budde K, Schütz M, Liefeldt L, Rudolph B, Schönemann C, Neumayer HH, Lachmann N. Waiser J, et al. Among authors: schutz m. Nephrol Dial Transplant. 2012 Mar;27(3):1246-51. doi: 10.1093/ndt/gfr465. Epub 2011 Aug 17. Nephrol Dial Transplant. 2012. PMID: 21852274

9

Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.

Budde K, Bosmans JL, Sennesael J, Zeier M, Pisarski P, Schütz M, Fischer W, Neumayer HH, Glander P. Budde K, et al. Among authors: schutz m. Clin Nephrol. 2007 Mar;67(3):164-75. doi: 10.5414/cnp67164. Clin Nephrol. 2007. PMID: 17390741 Clinical Trial.

10

New perspectives of immunosuppression.

Halleck F, Friedersdorff F, Fuller TF, Matz M, Huber L, Dürr M, Schütz M, Budde K. Halleck F, et al. Among authors: schutz m. Transplant Proc. 2013 Apr;45(3):1224-31. doi: 10.1016/j.transproceed.2013.02.033. Transplant Proc. 2013. PMID: 23622665 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

491 results

Search Page